Fate Therapeutics Stock Alpha and Beta Analysis
| FATE Stock | USD 1.00 0.01 0.99% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Fate Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Fate Therapeutics over a specified time horizon. Remember, high Fate Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Fate Therapeutics' market risk premium analysis include:
Beta 1.16 | Alpha 0.0634 | Risk 5.24 | Sharpe Ratio (0.04) | Expected Return (0.23) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Fate Therapeutics Backtesting, Fate Therapeutics Valuation, Fate Therapeutics Correlation, Fate Therapeutics Hype Analysis, Fate Therapeutics Volatility, Fate Therapeutics History and analyze Fate Therapeutics Performance. Fate Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Fate Therapeutics market risk premium is the additional return an investor will receive from holding Fate Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Fate Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Fate Therapeutics' performance over market.| α | 0.06 | β | 1.16 |
Fate Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Fate Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Fate Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Fate Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Fate Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Fate Therapeutics shares will generate the highest return on investment. By understating and applying Fate Therapeutics stock market price indicators, traders can identify Fate Therapeutics position entry and exit signals to maximize returns.
Fate Therapeutics Return and Market Media
The median price of Fate Therapeutics for the period between Tue, Sep 30, 2025 and Mon, Dec 29, 2025 is 1.1 with a coefficient of variation of 17.43. The daily time series for the period is distributed with a sample standard deviation of 0.21, arithmetic mean of 1.2, and mean deviation of 0.18. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Insider Trading | 10/20/2025 |
2 | Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635 | 11/04/2025 |
3 | Fate Therapeutics Expected to Announce Quarterly Earnings on Tuesday - MarketBeat | 11/05/2025 |
4 | Trends Strategies Shaping the 4.6 Billion Induced Pluripotent Stem Cells Market, 2025-2033 - Expanding Applications in Drug Discovery and Disease Modeling | 11/10/2025 |
5 | Fate Therapeutics GAAP EPS of -0.27 beats by 0.01, revenue of 1.74M beats by 0.06M | 11/13/2025 |
6 | Fate Therapeutics Announces Quarterly Earnings Results | 11/14/2025 |
7 | Brokerages Set Fate Therapeutics, Inc. Target Price at 3.92 | 11/21/2025 |
8 | Heres Why Were A Bit Worried About Fate Therapeutics Cash Burn Situation | 11/25/2025 |
9 | Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Ad... | 12/08/2025 |
10 | Why hedge funds are buying Fate Therapeutics Inc. stock - July 2025 Spike Watch Long-Term Growth Plans - | 12/18/2025 |
11 | Fate Therapeutics Shares Pass Below Two Hundred Day Moving Average - Whats Next - MarketBeat | 12/24/2025 |
About Fate Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Fate or other stocks. Alpha measures the amount that position in Fate Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 (projected) | Interest Debt Per Share | 1.13 | 1.05 | 0.75 | Revenue Per Share | 0.99 | 0.65 | 0.12 |
Fate Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Fate Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fate Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Fate Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Fate Therapeutics. Please utilize our Beneish M Score to check the likelihood of Fate Therapeutics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Fate Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Fate Therapeutics Backtesting, Fate Therapeutics Valuation, Fate Therapeutics Correlation, Fate Therapeutics Hype Analysis, Fate Therapeutics Volatility, Fate Therapeutics History and analyze Fate Therapeutics Performance. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Fate Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.